These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
153 related items for PubMed ID: 8244180
1. Salvage therapy in ovarian cancer: is there a role for intraperitoneal drug delivery? Markman M. Gynecol Oncol; 1993 Oct; 51(1):86-9. PubMed ID: 8244180 [Abstract] [Full Text] [Related]
2. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Markman M, Reichman B, Hakes T, Rubin S, Lewis JL, Jones W, Barakat R, Curtin J, Almadrones L, Hoskins W. Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150 [Abstract] [Full Text] [Related]
3. Current status of intraperitoneal therapy for ovarian cancer. Markman M. Curr Opin Obstet Gynecol; 1993 Feb; 5(1):99-104. PubMed ID: 7678757 [Abstract] [Full Text] [Related]
5. Role of intraperitoneal chemotherapy in the front-line setting. Markman M. J Clin Oncol; 2003 May 15; 21(10 Suppl):145s-148s. PubMed ID: 12743130 [Abstract] [Full Text] [Related]
6. Intraperitoneal therapy of ovarian cancer. Markman M. Semin Oncol; 1998 Jun 15; 25(3):356-60. PubMed ID: 9633848 [Abstract] [Full Text] [Related]
7. Gynecological malignancies. Schaebler DL, Schilder RJ, Young RC. Cancer Chemother Biol Response Modif; 1996 Jun 15; 16():564-91. PubMed ID: 8639401 [Abstract] [Full Text] [Related]
8. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study. Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS. Gynecol Oncol; 1998 Dec 15; 71(3):410-5. PubMed ID: 9887240 [Abstract] [Full Text] [Related]
9. Intraperitoneal chemotherapy in the management of malignant disease. Markman M. Expert Rev Anticancer Ther; 2001 Jun 15; 1(1):142-8. PubMed ID: 12113122 [Abstract] [Full Text] [Related]
10. Ifosfamide in the treatment of ovarian cancer. Markman M. Semin Oncol; 1996 Jun 15; 23(3 Suppl 6):47-9. PubMed ID: 8677449 [Abstract] [Full Text] [Related]
11. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. Markman M. Cancer J; 2009 Jun 15; 15(2):105-9. PubMed ID: 19390303 [Abstract] [Full Text] [Related]
12. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S, Yeap B, Vogl S, Carbone P. Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766 [Abstract] [Full Text] [Related]
13. Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma. Markman M. Semin Oncol; 1989 Aug 15; 16(4 Suppl 6):79-82. PubMed ID: 2669140 [Abstract] [Full Text] [Related]
14. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. Rao G, Crispens M, Rothenberg ML. J Clin Oncol; 2007 Jul 10; 25(20):2867-72. PubMed ID: 17617517 [Abstract] [Full Text] [Related]
15. Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer. Markman M. Semin Oncol; 1994 Apr 10; 21(2 Suppl 2):17-9; quiz 20, 58. PubMed ID: 8202717 [Abstract] [Full Text] [Related]
16. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. Forum (Genova); 2000 Apr 10; 10(4):323-32. PubMed ID: 11535983 [Abstract] [Full Text] [Related]